14,767 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Acquired by Mattson Financial Services LLC

Mattson Financial Services LLC purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 14,767 shares of the medical equipment provider’s stock, valued at approximately $1,603,000.

A number of other institutional investors have also recently bought and sold shares of the company. Speece Thorson Capital Group Inc. increased its holdings in Zimmer Biomet by 13.8% in the fourth quarter. Speece Thorson Capital Group Inc. now owns 158,202 shares of the medical equipment provider’s stock worth $19,253,000 after buying an additional 19,144 shares during the last quarter. M&G Plc bought a new position in Zimmer Biomet in the 1st quarter worth $7,397,000. AMF Tjanstepension AB bought a new position in Zimmer Biomet in the 1st quarter worth approximately $30,300,000. Factory Mutual Insurance Co. bought a new stake in Zimmer Biomet in the 1st quarter valued at $10,862,000. Finally, Gradient Investments LLC lifted its position in shares of Zimmer Biomet by 17.3% in the 2nd quarter. Gradient Investments LLC now owns 130,350 shares of the medical equipment provider’s stock worth $14,147,000 after acquiring an additional 19,224 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ZBH shares. Piper Sandler lowered shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $140.00 to $115.00 in a report on Monday, July 1st. Oppenheimer reduced their target price on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. TD Cowen reduced their price target on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a research report on Friday, September 6th. Raymond James cut their price objective on Zimmer Biomet from $138.00 to $128.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Tuesday, September 17th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $125.00.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $105.69 on Thursday. The company has a market cap of $21.74 billion, a price-to-earnings ratio of 22.88, a price-to-earnings-growth ratio of 1.98 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12-month low of $102.00 and a 12-month high of $133.90. The stock has a 50 day simple moving average of $109.45 and a 200-day simple moving average of $114.38. The company has a current ratio of 1.29, a quick ratio of 0.63 and a debt-to-equity ratio of 0.31.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The firm had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter in the prior year, the company earned $1.82 EPS. The company’s revenue was up 3.9% on a year-over-year basis. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date of this dividend is Monday, September 30th. Zimmer Biomet’s payout ratio is 20.78%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.